Immunophenotype of high-grade prostatic adenocarcinoma and urothelial carcinoma

被引:104
作者
Genega, EM
Hutchinson, B
Reuter, VE
Gaudin, PB
机构
[1] Hosp Univ Penn, Dept Pathol, Philadelphia, PA 19104 USA
[2] Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10021 USA
关键词
34 beta E12; CK; 7; immunohistochemistry; Leu; prostatic adenocarcinoma; PSA; PSAP; urothelial carcinoma;
D O I
10.1038/modpathol.3880220
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Morphologic features alone can usually be used to distinguish prostatic adenocarcinoma and urothelial carcinoma of the urinary bladder. Poorly differentiated tumors, however, can occasionally have features of both neoplasms, making determination of site of origin difficult, No study has provided a panel of antibodies to assist in the distinction of these two tumors. For this study, 73 examples of moderately and poorly differentiated prostatic adenocarcinoma and 46 examples of high-grade urothelial carcinoma were obtained from radical resection specimens. Immunohistochemical studies were performed using the following panel of antibodies: cytokeratin (CK) 7, CK 20, 34 beta E12 Leu M1, carcinoembryonic antigen (CEA)m, CEAp, p53, Leu 7, prostate-specific acid phosphatase (PSAP), prostate-specific antigen (PSA), and B72.3. Mucicarmine was also performed. Intermediate and high-grade prostatic carcinoma were compared and then high-grade prostatic carcinoma was compared with high-grade urothelial carcinoma PSA and PSAP each stained 94% of prostatic adenocarcinomas, but no urothelial carcinomas. Leu 7 stained 94% of prostate and 17% of urothelial carcinomas. Over half of the urothelial carcinomas showed positivity for 34 beta E12 (65%), as did two cases of prostatic carcinoma (6%). Eighty-three percent of urothelial carcinomas and 12% of prostatic adenocarcinomas stained with CK 7. Forty-one percent of urothelial carcinomas and 12% of prostatic carcinomas were reactive for CEAm, and p53 stained 33% and 3% of urothelial and prostatic adenocarcinomas, respectively. No significant difference was seen in the expression of CEAp, CK 20, B72.3, Leu Mi, or mucicarmine between prostate and urothelial carcinoma We propose a panel of six antibodies to assist in the distinction of high-grade prostatic adenocarcinoma from high grade urothelial carcinoma: PSA, PSAP, 34 beta E12 Leu 7, CK7, and p53. The first three antibodies should be used initially; if results are negative, the remaining antibodies may be employed.
引用
收藏
页码:1186 / 1191
页数:6
相关论文
共 50 条
[1]  
ABO T, 1981, J IMMUNOL, V127, P1024
[2]   IMMUNOHISTOCHEMICAL DETERMINATION OF P53 PROTEIN NUCLEAR ACCUMULATION IN PROSTATIC ADENOCARCINOMA [J].
APRIKIAN, AG ;
SARKIS, AS ;
FAIR, WR ;
ZHANG, ZF ;
FUKS, Z ;
CORDONCARDO, C .
JOURNAL OF UROLOGY, 1994, 151 (05) :1276-1280
[3]  
BATTIFORA H, 1986, LAB INVEST, V55, P244
[4]   IMMUNOHISTOCHEMICAL DEMONSTRATION OF PROSTATIC ORIGIN OF METASTASES [J].
BENTZ, MS ;
COHEN, C ;
DEMERS, LM ;
BUDGEON, LR .
UROLOGY, 1982, 19 (06) :584-586
[5]  
BRAWER MK, 1985, CANCER RES, V45, P3663
[6]   TAG-72 EXPRESSION IN PRIMARY, METASTATIC AND HORMONALLY TREATED PROSTATE-CANCER AS DEFINED BY MONOCLONAL-ANTIBODY CC49 [J].
BRENNER, PC ;
RETTIG, WJ ;
SANZMONCASI, MP ;
REUTER, V ;
APRIKIAN, A ;
OLD, LJ ;
FAIR, WR ;
GARINCHESA, P .
JOURNAL OF UROLOGY, 1995, 153 (05) :1575-1579
[7]  
CARTUN RW, 1989, J HISTOTECHNOL, V12, P273
[8]  
DALBAGNI G, 1993, DIAGN MOL PATHOL, V2, P4, DOI 10.1097/00019606-199300020-00002
[9]   MULTIPLE IMMUNOPEROXIDASE MARKERS IN BENIGN HYPERPLASIA AND ADENOCARCINOMA OF THE PROSTATE [J].
ELLIS, DW ;
LEFFERS, S ;
DAVIES, JS ;
NG, ABP .
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 1984, 81 (03) :279-284
[10]  
EPSTEIN JI, 1993, UROL CLIN N AM, V20, P757